Lung cancer is the second most common type of cancer and is the leading cause of cancer death globally. In 2018, almost 2.1 million new cases were diagnosed, accounting for ~12% of the cancer burden worldwide. The malignant stage of lung tumor is known as lung adenocarcinoma, which is most common and is diagnosed in both smokers and non-smokers.
There are two main types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Genomic studies have indicated that more than 80% of lung malignancies are classified as NSCLC, of which adenocarcinoma is a predominant subtype. Although significant progress has been made in treating tumor with targetable driver mutations, like EGFR mutations, most tumor do not have such mutations and the prognosis remains poor for metastasis stage patients. Platinum doublet chemotherapy has been the mainstay first-line treatment of patients who are diagnosed with metastatic lung adenocarcinoma without a targetable mutation.
In recent years, immunotherapy has emerged as a treatment option that has shown strong response in a subset of patients. The immune agents block crucial checkpoints and regulate the immune response, but the tumor cells evade the patient’s immune systems. By blocking these receptor–ligand interactions, a particular subset of T cells is activated to recognize and respond to tumor cells. While such responses to immunotherapy are promising, they have only been effective in ~20% of patients.
Therefore, there is urgent need to understand the underlying mechanism of lung adenocarcinoma from genome to immunotherapy. To address this unmet need, this Research Topic will focus on advancements related to lung adenocarcinoma. We welcome original research articles, systematic review, meta-analysis, clinical case studies, and review articles within the scope of the research topic. Bioinformatics studies are welcome; however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated. The submissions can include but not limited to the following subtopics:
• Identifying molecular targets, regulators, and genetic and epigenetic mechanisms that underlie lung adenocarcinoma.
• Identifying protein-protein interaction, protein-drug interaction and drug target identification for lung adenocarcinoma.
• Functional characterization of genetic variants and new therapy approaches for lung adenocarcinoma.
• Studies addressing the In-silico approaches for prediction and the genomic markers with risk factors involved in lung adenocarcinoma.
• Molecular therapeutic mechanisms and clinical studies related to lung adenocarcinoma.
• Novel prognostic biomarkers in lung adenocarcinoma.
Lung cancer is the second most common type of cancer and is the leading cause of cancer death globally. In 2018, almost 2.1 million new cases were diagnosed, accounting for ~12% of the cancer burden worldwide. The malignant stage of lung tumor is known as lung adenocarcinoma, which is most common and is diagnosed in both smokers and non-smokers.
There are two main types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Genomic studies have indicated that more than 80% of lung malignancies are classified as NSCLC, of which adenocarcinoma is a predominant subtype. Although significant progress has been made in treating tumor with targetable driver mutations, like EGFR mutations, most tumor do not have such mutations and the prognosis remains poor for metastasis stage patients. Platinum doublet chemotherapy has been the mainstay first-line treatment of patients who are diagnosed with metastatic lung adenocarcinoma without a targetable mutation.
In recent years, immunotherapy has emerged as a treatment option that has shown strong response in a subset of patients. The immune agents block crucial checkpoints and regulate the immune response, but the tumor cells evade the patient’s immune systems. By blocking these receptor–ligand interactions, a particular subset of T cells is activated to recognize and respond to tumor cells. While such responses to immunotherapy are promising, they have only been effective in ~20% of patients.
Therefore, there is urgent need to understand the underlying mechanism of lung adenocarcinoma from genome to immunotherapy. To address this unmet need, this Research Topic will focus on advancements related to lung adenocarcinoma. We welcome original research articles, systematic review, meta-analysis, clinical case studies, and review articles within the scope of the research topic. Bioinformatics studies are welcome; however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated. The submissions can include but not limited to the following subtopics:
• Identifying molecular targets, regulators, and genetic and epigenetic mechanisms that underlie lung adenocarcinoma.
• Identifying protein-protein interaction, protein-drug interaction and drug target identification for lung adenocarcinoma.
• Functional characterization of genetic variants and new therapy approaches for lung adenocarcinoma.
• Studies addressing the In-silico approaches for prediction and the genomic markers with risk factors involved in lung adenocarcinoma.
• Molecular therapeutic mechanisms and clinical studies related to lung adenocarcinoma.
• Novel prognostic biomarkers in lung adenocarcinoma.